8 High-dose megestrol acetate in advanced ovarian cancer: A phase II study

1987 ◽  
Vol 28 ◽  
pp. 215
Author(s):  
C.H.N. Veenhof ◽  
M.E.L. van der Burg ◽  
F. Carnino ◽  
M. Forni ◽  
C.F. de Oliveira ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Ovarian Cancer ◽  
Megestrol Acetate ◽  
High Dose

High-dose platinum chemotherapy in advanced ovarian cancer: A phase II study

1992 ◽  
Vol 44 (1) ◽  
pp. 79-82 ◽  
Author(s):  
Kamma Bertelsen ◽  
Lars Bastholt
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Ovarian Cancer ◽  
High Dose ◽  
Platinum Chemotherapy

Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

1998 ◽  
Vol 16 (5) ◽  
pp. 1852-1860 ◽  
Author(s):  
C Aghajanian ◽  
D Fennelly ◽  
F Shapiro ◽  
R Waltzman ◽  
L Almadrones ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Pathologic Complete Response ◽  
Advanced Ovarian Cancer ◽  
Complete Response ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Pilot Phase ◽  
Experienced Grade

PURPOSE We performed a pilot phase II study to evaluate the potential for delivery of rapidly sequenced high-dose chemotherapy treatments rescued with autologous peripheral-blood progenitor cells (PBP) in patients with previously untreated, advanced ovarian cancer. PATIENTS AND METHODS A single cycle of mobilization was used, primed with cyclophosphamide (CPA)/paclitaxel (Txl) and filgrastim (granulocyte colony-stimulating factor [G-CSF]), followed by three cycles of high-dose carboplatin (CBDCA)/Txl and one cycle of high-dose melphalan (MEL), each rescued by PBP. We then analyzed the outcome for a total of 56 consecutive patients treated with high-dose chemotherapy as part of this program. RESULTS In the phase II pilot, 21 patients were enrolled. There were no treatment-related deaths through 98 high-dose treatments, although 34 treatments were complicated by hospitalization, primarily for neutropenic fever. Seventy-six percent of patients experienced grade 3 to 4 gastrointestinal toxicity and 62% experienced grade 2 to 3 neuropathy. Five of 15 (33%) patients who underwent second-look surgery attained a pathologic complete response. In the overall analysis, 56 patients were reviewed. Forty-four patients were assessable for response by second-look surgery or clinical progression. Fifteen of 44 patients achieved a pathologic complete response (34%). The pathologic complete response rate in optimal-disease patients was 12 of 22 (55%), while only three of 22 (13%) suboptimal stage III and IV patients achieved a pathologic complete response. CONCLUSION The Gynecologic Oncology Group has initiated a pilot phase II trial of this approach in patients with optimally debulked stage III ovarian cancer. There is no evidence to support the use of this or other aggressive regimens outside of a clinical trial.

Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer

2001 ◽  
Vol 12 (9) ◽  
pp. 719-724 ◽  
Author(s):  
Sarikapan Wilailak ◽  
Vasant Linasmita ◽  
Somkeart Srisupundit
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Megestrol Acetate ◽  
High Dose ◽  
Platinum Refractory

Paclitaxel-cisplatin combination in advanced ovarian cancer: a phase II study

2000 ◽  
Vol 5 (2) ◽  
pp. 85-88
Author(s):  
T. Sugiyama ◽  
M. Yakushiji ◽  
Y. Aoki ◽  
K. Tanaka ◽  
R. Nishimura ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Ovarian Cancer

Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: A Kansai Clinical Oncology Group study (KCOG9812)

2013 ◽  
Vol 128 (1) ◽  
pp. 22-27 ◽  
Author(s):  
Hiroshi Tsubamoto ◽  
Yoshio Itani ◽  
Kimihiko Ito ◽  
Riichiro Kanazawa ◽  
Shinji Toyoda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Oncology ◽  
Phase Ii ◽  
Intraperitoneal Chemotherapy ◽  
Phase Ii Study ◽  
Advanced Ovarian Cancer ◽  
Oncology Group ◽  
Debulking Surgery ◽  
Oncology Group Study ◽  
Interval Debulking Surgery

Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer

2006 ◽  
Vol 100 (2) ◽  
pp. 318-323 ◽  
Author(s):  
M.O. Nicoletto ◽  
C. Falci ◽  
D. Pianalto ◽  
G. Artioli ◽  
P. Azzoni ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Study ◽  
Advanced Ovarian Cancer ◽  
Pegylated Liposomal Doxorubicin

A phase II study of two induction schedules of high dose carboplatin (HDC) vs weekly paclitaxel/gemcitabine (WPG) followed by paclitaxel/carboplatin/gemcitabine (PCG) in advanced ovarian cancer (AOC)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15062-15062
Author(s):  
G. Bolis ◽  
G. Polverino ◽  
C. Sciatta ◽  
G. Scarfone ◽  
G. Scambia
Keyword(s):  
Phase Ii ◽  
Residual Disease ◽  
Phase Ii Study ◽  
Active Agent ◽  
Advanced Ovarian Cancer ◽  
Figo Stage ◽  
High Dose ◽  
Stage Iiic ◽  
Standard Regimen ◽  
Grade 3

15062 Background: Patients (pts) with newly diagnosed AOC generally receive platinum plus taxane therapy. G represents a new active agent to improve the standard regimen. To investigate the safety of two schedules of induction treatments both followed by triplet PCG we have drafted a phase II study. Methods: 14 pts, suboptimally debulked (FIGO stage IIIc) entered the study. HDC ( AUC 7,5) was administered for 2 courses every 21 days ( arm A) and P ( 80 mg/sqm, d 1,8,15,22) + G ( 2500 mg/sqm, d 1,15) (arm B). Both regimens have been followed by standard triplet P ( 175 mg/sqm, d1) + C ( AUC 5, d1) + G ( 800 mg/sqm, d1,8) every 21 days for a total of 6 courses. Antiemetics, corticoids, antihistaminics and ranitidine have been added. Results: The median age was 57 y (39–68). Histology was serous in 64.3%, mixed 14.3% and other 21.4%. All pts had Grade 3 tumor but one. Seven pts received arm A schedule and 7 arm B both followed by PCG regimen. Worst haematological toxicities ( in term of nadir) observed in all courses for all pts were neutropenia G4 ( 42.8% arm A vs 71.4% arm B), anemia G2 (71.4% arm A vs 57.1% arm B), thrombocytopenia G2 ( 57.1% arm A vs 42.8% arm B). Most common non haematological toxicities were alopecia and mild nausea/vomiting. Mild paresthesias in both regimens were observed. No sepsis or neutropenic fever nor unespected toxicity or treatment-related deaths were observed. 71.4% of pts completed foreseen schedules of treatments. 78.5% of pts received erytropoietin and 28.5% G-CSF support. Conclusions: HDC and weekly PG followed by triplet PCG are feasible and safety regimens in AOC pts ( residual disease > 1 cm). Further phase II-III setting study using these schedules will be conducted. No significant financial relationships to disclose.

Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 5015-5015
Author(s):  
R. W. Holloway ◽  
M. Roche ◽  
L. DeMars ◽  
J. A. Williams ◽  
A. Enke ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Ovarian Cancer ◽  
Complete Response ◽  
Response To Chemotherapy

First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 5071-5071
Author(s):  
G. Oskay-Özcelik ◽  
R. Richter ◽  
K. Pietzner ◽  
H. Hindenburg ◽  
H. L. Sommer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Ovarian Cancer ◽  
German Society ◽  
Life Data ◽  
Multicenter Phase ◽  
Dose Dense
Sign in / Sign up

Export Citation Format

Share Document